Saturday, September 11, 2010
"Concise industry news from the US pharmaceutical industry..."
Blog
Where our team of guest writers discuss what they think about the current NGP US Issues.
Peter Duncan
Director of Business Development
Director of Business Development
Can digital pathology save drug development?
Peter Duncan of Definiens discusses the potential of digital pathology.07 Jul 2010
Life sciences in the fast lane
Deloitte Consulting | www.deloitte.comenergy
No Comments
Two things are certain in life sciences ? not exactly death and taxes, yet quite similar in nature.
Includes:
Key challenges
The bottom line ? pricing
Manufacturing and regulatory issues
Patent uncertainty
Bio-pharma alliances ? making 1 + 1 = 3
More like this...
-
A new approach to outsourced pharmaceutical man...
Pharmaceutical companies face a myriad of challenges day in and day out.Read more -
Strategic outsourcing: the viable option
This article looks at two very different approaches to outsourcing.Read more -
Risk and quality management ? a supplier?s pers...
In September 2004, the FDA issued a final report on its Pharmaceutical Manufacturing Initiative (PMI).Read more -
Size isn?t everything
NGP talks with Scott Mize, President of Foresight Institute, about the vast implications that the tiny world of nanotechnology could have for life sciences.Read more
Disclaimer: All comments posted in a personal capacity
No Comments Have Been Submitted
Disclaimer: All comments posted in a personal capacity
Source: www.ngpharma.com© 2010 GDS Publishing Ltd. All rights reserved.